Nanoalbumon (Human Serum Albumin)

Human Serum Albumin, the active ingredient in Nanoalbumon, is an albumin presented as an unknown/unknown for intravenous use. It restores plasma oncotic pressure and expands intravascular volume in patients who require rapid volume replacement, such as those with hypovolemia or severe burns.

GNH USA supplies Nanoalbumon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Nanoalbumon, a human serum albumin solution, is used in clinical situations that require plasma volume expansion and oncotic support. - Hypovolemia: restores circulating volume and improves tissue perfusion. - Burn injuries: provides oncotic pressure to reduce edema and support fluid resuscitation. - Major surgery: maintains intravascular volume and stabilises haemodynamics. - Trauma: helps counteract blood loss and supports circulatory stability. - Severe hypoalbuminemia: raises serum albumin levels and improves oncotic balance.

Human Serum Albumin may be associated with a range of adverse reactions, most of which are related to infusion and immune response.

Common Side Effects: - Fever or chills during infusion. - Transient hypotension or hypertension. - Mild allergic rash or urticaria. - Nausea or vomiting. - Headache. - Local site irritation.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction. - Volume overload leading to pulmonary edema. - Hemolysis. - Thromboembolic events. - Sepsis from contaminated product. - Acute renal failure.

When using Nanoalbumon, clinicians should observe several safety measures to minimise risk. - Allergy assessment: confirm no known hypersensitivity to human albumin. - Volume status: monitor for signs of fluid overload, especially in cardiac patients. - Cardiac function: use cautiously in heart failure or ischemic heart disease. - Renal function: adjust monitoring in patients with renal impairment. - Electrolyte balance: check serum electrolytes before and during therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human Serum Albumin can influence the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Diuretics: may exacerbate intravascular volume depletion. - Cardiovascular agents (e.g., nitrates): risk of profound hypotension.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): albumin binding may alter INR, requiring monitoring. - Nephrotoxic drugs (e.g., aminoglycosides): monitor renal function closely. - Vasopressors: dose adjustments may be needed due to changes in plasma volume.